156 related articles for article (PubMed ID: 31259249)
1. The Value of Progression-Free Survival in Metastatic Breast Cancer: Results From a Survey of Patients and Providers.
MacEwan JP; Doctor J; Mulligan K; May SG; Batt K; Zacker C; Lakdawalla D; Goldman D
MDM Policy Pract; 2019; 4(1):2381468319855386. PubMed ID: 31259249
[No Abstract] [Full Text] [Related]
2. Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment.
Liu FX; Witt EA; Ebbinghaus S; DiBonaventura Beyer G; Shinde R; Basurto E; Joseph RW
Patient Prefer Adherence; 2017; 11():1389-1399. PubMed ID: 28860722
[TBL] [Abstract][Full Text] [Related]
3. Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.
Michiels S; Pugliano L; Marguet S; Grun D; Barinoff J; Cameron D; Cobleigh M; Di Leo A; Johnston S; Gasparini G; Kaufman B; Marty M; Nekljudova V; Paluch-Shimon S; Penault-Llorca F; Slamon D; Vogel C; von Minckwitz G; Buyse M; Piccart M
Ann Oncol; 2016 Jun; 27(6):1029-1034. PubMed ID: 26961151
[TBL] [Abstract][Full Text] [Related]
4. What Is Important When Making Treatment Decisions in Metastatic Breast Cancer? A Qualitative Analysis of Decision-Making in Patients and Oncologists.
Rocque GB; Rasool A; Williams BR; Wallace AS; Niranjan SJ; Halilova KI; Turkman YE; Ingram SA; Williams CP; Forero-Torres A; Smith T; Bhatia S; Knight SJ
Oncologist; 2019 Oct; 24(10):1313-1321. PubMed ID: 30872466
[TBL] [Abstract][Full Text] [Related]
5. Use of the metastatic breast cancer progression (MBC-P) questionnaire to assess the value of progression-free survival for women with metastatic breast cancer.
Hurvitz SA; Lalla D; Crosby RD; Mathias SD
Breast Cancer Res Treat; 2013 Dec; 142(3):603-9. PubMed ID: 24218050
[TBL] [Abstract][Full Text] [Related]
6. Patient and Oncology Nurse Preferences for the Treatment Options in Advanced Melanoma: A Discrete Choice Experiment.
Liu FX; Witt EA; Ebbinghaus S; DiBonaventura Beyer G; Basurto E; Joseph RW
Cancer Nurs; 2019; 42(1):E52-E59. PubMed ID: 29076867
[TBL] [Abstract][Full Text] [Related]
7. Progression-free survival and quality of life in metastatic breast cancer: The patient perspective.
Mertz S; Benjamin C; Girvalaki C; Cardone A; Gono P; May SG; Comerford E; Than KS; Birch K; Roach M; Myers S; Sasane M; Lavi L; Cameron A; Cardoso F
Breast; 2022 Oct; 65():84-90. PubMed ID: 35870420
[TBL] [Abstract][Full Text] [Related]
8. "I'd Want to Know, Because a Year's Not a Long Time to Prepare for a Death": Role of Prognostic Information in Shared Decision Making among Women with Metastatic Breast Cancer.
Niranjan SJ; Turkman Y; Williams BR; Williams CP; Halilova KI; Smith T; Knight SJ; Bhatia S; Rocque GB
J Palliat Med; 2020 Jul; 23(7):937-943. PubMed ID: 32043896
[No Abstract] [Full Text] [Related]
9. Pembrolizumab for Previously Treated Advanced or Metastatic Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Gallacher D; Armoiry X; Auguste P; Court R; Mantopoulos T; Patterson J; De Santis M; Cresswell J; Mistry H
Pharmacoeconomics; 2019 Jan; 37(1):19-27. PubMed ID: 30030817
[TBL] [Abstract][Full Text] [Related]
10. Understanding Clinician Preferences for Treatment Attributes in Oncology: A Discrete Choice Experiment of Oncologists' and Urologists' Preferences for First-Line Treatment of Locally Advanced/Unresectable Metastatic Urothelial Carcinoma in Five European Countries.
Panattoni L; Kearney M; Land N; Flottemesch T; Sullivan P; Kirker M; Bharmal M; Hauber B
Pharmacoeconomics; 2024 Mar; ():. PubMed ID: 38472738
[TBL] [Abstract][Full Text] [Related]
11. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
Wagner AD; Thomssen C; Haerting J; Unverzagt S
Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
[TBL] [Abstract][Full Text] [Related]
12. Patient and physician preferences for anticancer drugs for the treatment of metastatic colorectal cancer: a discrete-choice experiment.
González JM; Ogale S; Morlock R; Posner J; Hauber B; Sommer N; Grothey A
Cancer Manag Res; 2017; 9():149-158. PubMed ID: 28490902
[TBL] [Abstract][Full Text] [Related]
13. Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer?
Amir E; Seruga B; Kwong R; Tannock IF; Ocaña A
Eur J Cancer; 2012 Feb; 48(3):385-8. PubMed ID: 22115991
[TBL] [Abstract][Full Text] [Related]
14. Benefit-risk trade-offs in treatment choice in advanced HER2 negative breast cancer: patient and oncologist perspectives.
Amin S; Tolaney SM; Cambron-Mellott MJ; Beusterien K; Maculaitis MC; Mulvihill E; Shinde R; McLaurin K
Future Oncol; 2022 May; 18(16):1927-1941. PubMed ID: 35249366
[TBL] [Abstract][Full Text] [Related]
15. Should we involve patients more actively? Perspectives of the multidisciplinary team on shared decision-making for older patients with metastatic castration-resistant prostate cancer.
de Angst IB; Kil PJM; Bangma CH; Takkenberg JJM
J Geriatr Oncol; 2019 Jul; 10(4):653-658. PubMed ID: 30639265
[TBL] [Abstract][Full Text] [Related]
16. Correlation between progression-free survival and overall survival in metastatic breast cancer patients receiving anthracyclines, taxanes, or targeted therapies: a trial-level meta-analysis.
Adunlin G; Cyrus JW; Dranitsaris G
Breast Cancer Res Treat; 2015 Dec; 154(3):591-608. PubMed ID: 26596731
[TBL] [Abstract][Full Text] [Related]
17. Patient Preferences Regarding Chemotherapy in Metastatic Breast Cancer-A Conjoint Analysis for Common Taxanes.
Spaich S; Kinder J; Hetjens S; Fuxius S; Gerhardt A; Sütterlin M
Front Oncol; 2018; 8():535. PubMed ID: 30519542
[No Abstract] [Full Text] [Related]
18. Correlation between overall survival and other endpoints in metastatic breast cancer with second- or third-line chemotherapy: Literature-based analysis of 24 randomized trials.
Liu L; Chen F; Zhao J; Yu H
Bull Cancer; 2016 Apr; 103(4):336-44. PubMed ID: 26874974
[TBL] [Abstract][Full Text] [Related]
19. Patient Preferences: Results of a German Adaptive Choice-Based Conjoint Analysis (Market Research Study Sponsored by Eli Lilly and Company) in Patients on Palliative Treatment for Advanced Breast Cancer.
Reinisch M; Marschner N; Otto T; Korfel A; Stoffregen C; Wöckel A
Breast Care (Basel); 2021 Oct; 16(5):491-499. PubMed ID: 34720809
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
